QuantHealth, a company that uses AI to simulate clinical trials before they run, has raised $45 million in Series B funding. The round was led by Qumra Capital, with participation from Sanofi Ventures, Pitango HealthTech, and several other investors. The company says it will use the money to expand research, grow its workforce, and broaden its product portfolio after reporting eightfold sales growth in 2025.
The platform lets pharmaceutical and biotech companies test trial designs, optimize protocols, and predict failures before enrolling a single patient. QuantHealth says it aims to replace the industry's traditional approach - relying on historical benchmarks and running expensive real-world iterations - with predictive simulations that cut risk and capital exposure.
Why clinical trials need better planning
More than 90% of drugs that enter clinical development eventually fail, and about 75% of those failures are due to efficacy or safety issues, according to QuantHealth. That failure rate makes clinical trials one of the most expensive and uncertain parts of drug development, pressuring companies to adopt predictive tools earlier in the process.
QuantHealth's simulations have covered more than 600 trials across 30 indications, reaching up to 90% predictive accuracy. The company plans to expand to over 40 indications, focusing on oncology, cardiometabolic disease, and inflammation. It already works with 12 of the world's top 20 pharmaceutical companies.
What the funding will do
"Today, clinical development decisions are still largely made through real-world iteration - running trials, waiting for results and adjusting at significant cost and risk. We're fundamentally changing that model," said Orr Inbar, CEO and co-founder of QuantHealth. "With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital. This funding allows us to scale that approach, making simulation a standard step in development and fundamentally improving how drugs are brought to market."
Reut Yehuda Golan, partner at Qumra Capital, said: "AI has already transformed drug discovery, and clinical trials are the next frontier. It's a market in which hundreds of billions of dollars are spent annually on clinical trials, and one that is ripe for a smarter, more efficient approach."
QuantHealth did not disclose its valuation. The series B follows eightfold sales growth in 2025, which the company cites as evidence of market demand for its approach. For professionals in product development, the platform represents a shift toward using AI for product development to simulate outcomes before committing resources - a capability that applies beyond pharma to any high-stakes, iterative design process. In the healthcare sector specifically, this kind of predictive simulation is part of a broader move toward AI for healthcare that reduces trial-and-error costs.
Why this matters for product development
For product development professionals, QuantHealth's model shows how simulation can replace costly real-world iteration with data-driven prediction. Whether you build drugs or software, the underlying principle is the same: test your design assumptions before you build, adjust fast, and kill failing ideas early. That approach cuts wasted time and capital - and it's a standard that drug developers are now starting to adopt at scale.
Your membership also unlocks:
